Optimization of bead coating. Beads were coated with various concentrations of Rac1, incubated with FL-GTP and the bead fluorescence measured on the iQue®. Max refers to signal in the absence of 0.5 mM unlabeled GTP, min refers to signal in the presence of 0.5 mM unlabeled GTP.
High throughput (HT) screening is at the starting point for most drug discovery programs. As the range of targets being pursued widens new technologies have to be deployed to enable assays built to measure the activity of proteins previously deemed challenging. Flow cytometry is a technology providing multi-parametric analysis of single cells or other particles in suspension, such as beads. High throughput (HT) flow cytometry has become a very attractive screening platform for drug discovery. In this chapter we describe a 1536 well format high throughput screen of 500,000 compounds to find inhibitors of Rac1 GTPase to prevent allergic airway hyper-responsiveness in asthma. We discuss the assay development, miniaturization and validation carried out prior to the full screening campaign. We then describe how we have automated our iQue® HD screener instruments and how we proceed with the data analysis and explain why we chose to run this screen on a flow cytometer and how it enabled us to reduce cost and timelines for the project.
- drug discovery
- bead-based assay
Asthma is a heterogeneous inflammatory disorder of the airways characterized by chronic deregulated inflammation, bronchial hyperreactivity, and symptoms of recurrent wheezing, coughing, and shortness of breath. Its prevalence has increased considerably over the past three decades, particularly in Western countries. Asthma is a major public health problem that affects 300 million people worldwide [1, 2].
Airway hyperresponsiveness (AHR), one of the hallmarks of asthma, directly results from excessive contraction of airway smooth muscle cells (aSMC). The degree of AHR always correlates with asthma severity and the need for therapy [3, 4]. Regular treatment of chronic asthma consists of a combination of inhaled anti-inflammatory corticosteroids and long-acting beta2-adrenergic receptor agonists for bronchodilation. However, severe asthma escapes to usual treatments or frequently requires higher doses. In acute asthma, short-acting beta2 agonists or anticholinergics are used as bronchodilators. These drugs are rapidly effective but can be insufficient in some cases of severe acute asthma attack. Despite available therapies, many patients with severe asthma remain uncontrolled and the number of asthma deaths is still elevated . There is thus an obvious need for new drugs acting through other pathways to prevent or reverse AHR and decrease severe asthma attacks, hospitalizations and deaths.
The molecular mechanisms regulating aSMC contraction and proliferation involved in AHR are still largely unknown. Understanding the intracellular signaling pathways responsible for AHR is thus essential to identify new targets and design new treatments. In this way, the Rho protein Rac1 has been identified as a promising candidate.
The Rho/Rac proteins constitute a family of small GTPases of more than 25 members in mammals. So far, the best characterized members of this family include the members of the Rho (RhoA, RhoB, RhoC), Rac (Rac1, Rac2, RhoG), and Cdc42 (Cdc42) subfamilies. Rho/Rac proteins share a common structure (40–95% identity) composed of a six-stranded mixed β sheet flanked by five α helices. The core G domain is made up of five polypeptide loops (G1–G5) involved in nucleotide, regulators and effectors interactions. Like the majority of Ras superfamily GTPases, most members of the Rho/Rac family behave as molecular switches that cycle between inactive (GDP-bound) and active (GTP-bound) states. In basal conditions, these proteins are inactive and sequestered in the cytosol due to their binding to Rho GDP dissociation inhibitors (RhoGDIs). Upon cell stimulation, Rho proteins became GTP-bound, translocate to the plasma membrane after release from RhoGDI, and interact with their primary effector molecules to trigger different signal transduction pathways. In addition to RhoGDIs, the activation/inactivation cycle of Rho/Rac proteins is regulated by a complex set of regulatory proteins that include GDP/GTP exchange factors (GEFs) and GTPase activating protein (GAPs) (Figure 1). Interaction of Rho/Rac protein with a GEF promotes the exchange of GDP for GTP molecules, thus leading to the rapid activation of Rho/Rac proteins during cell stimulation events. By contrast, GAPs promote the hydrolysis of the bound GTP molecules to GDP, thus allowing the transfer of the GTPases back to the inactive state at the end of the stimulation cycle .
During the last decade, Rho/Rac protein signaling pathways have been recognized as major regulators of essential cellular functions. Rac1 is a key regulator of cytoskeletal structure and dynamics, leading to lamellipodia and ruffle formations [6, 7]. Thanks to this last function, Rac1 controls cellular migration and adhesion. Recently, we demonstrated that Rac1 regulates vascular SMC contraction, and consequently modulates arterial pressure . Accordingly, we hypothesized that Rac1 could also be involved in aSMC contraction. We demonstrated that the specific SMC deletion of Rac1 (SM-Rac1-KO) in mice prevents bronchoconstriction
Unfortunately, the currently available drugs that inhibit Rac1 (EHT 1864 and NSC23766) have low affinity and induce critical off-target effects, thus highlighting the obvious need to discover new Rac inhibitors [9, 10].
In this chapter we describe how a published flow cytometry assay was taken and converted to a 1536 well format suitable for high throughput screening (HTS) to enable the screening of 500,000 compounds in the AstraZeneca Global HTS Centre to attempt to find new Rac1 inhibitors. We describe the whole protocol from receiving assay ready plates through to the data analysis and discuss the criteria that are important for an assay to be suitable for a high throughput screen by flow cytometry and describe the validation process we go through prior to starting a high throughput screening campaign.
2. Assay development
Several papers have demonstrated the utility of a bead-based flow cytometric GTP-binding assay for screening GTPase targets for small molecule inhibitors in both singleplex and multiplex formats [11, 12, 13]. As part of AstraZeneca’s Open Innovation initiative, we collaborated with researchers at l’Institut du thorax to identify small molecule inhibitors of Rac1 GTPase. We therefore set out to develop a bead-based assay for screening Rac1 in a singleplex fashion (Figure 2) for a screening campaign in 1536 well plates on an iQue® Screener HD. The Intellicyt iQue® Screener HD is a flow cytometer with an autosampler able to sample from 96, 384 and 1536 well plates. Using proprietary technology the instrument separates well samples with an air bubble allowing the software to determine what sample comes from what well making the instrument a true high throughput instrument.
The assay is based on glutathione-coated beads used to capture GST-tagged Rac1. Bodipy-labeled GTP (FL-GTP, ThermoFisher Scientific), is then used as a tracer for the detection of compounds that compete with its binding to the GTPase resulting in a decreased fluorescence signal.
We purchased commercially-available glutathione coated particles (GSH beads, size 4.0–4.9 μm, Spherotech) that have glutathione covalently coupled to their surface and glutathione S-transferase tagged Rac1 protein (human wild type) (GST-Rac1, ThermoFisher Scientific) and bound the GST-Rac1 onto the GSH beads overnight. Assay development was performed in 384 well plates before miniaturizing the assay for 1536 well plates. We optimized the concentration of FL-GTP to use in the assay to achieve the largest signal to background window and also confirmed that FL-GTP did not bind to unconjugated beads to demonstrate Rac1/GTP binding specificity. Based on the data shown in Figure 3 and associated table, 100 nM FL-GTP was selected.
To validate that the beads were coated with GST-Rac1 and that they would bind bodipy-labeled GTP the prepared beads were mixed with serial dilutions of unlabeled GTP (ThermoFisher Scientific) as a competitor followed by the addition of FL-GTP. To prepare the assay, 5 μL of coated beads were dispensed into wells on a 384 well plate followed by 5 μL of buffer containing unlabeled GTP in serial dilutions in triplicate, then 5 μL of 100 nM FL-GTP was added for a final volume of 15 μL and incubated for 30 min. The methods described in Refs. [11, 12, 13] included a final incubation for up to 60 min at 4
Addition of unlabeled GTP was able to compete with FL-GTP under all assay conditions in a concentration-dependent manner (Figure 5). Samples incubated at 4
The challenge for us was to perform the assay in a 1536-well format in order to minimize both cost and timelines of the screen.
Miniaturization to 1536 well format was first performed by using blank GSH beads to test dispensing, inter-well shake speeds, and sip times. Runs were repeated under various conditions to determine the optimum protocol. During these runs it was determined that it was best to use the bead sample buffer 0.1% (w/v) BSA in NP-HPS (30 mM HEPES pH 7.2, 100 mM KCl, 20 mM NaCl, 0.01% NP-40) supplemented with 1 mM DTT to prime the system before acquisition and during inter-well shaking. We found that we could decrease the sip time during which the sample probe aspirates from the well to 0.5 s per well, resulting in the acquisition of an entire 1536 well plate in under 50 min. Once the iQue® Screener HD protocol was optimized with blank GSH beads, we ran 3 separate plates with ½ of the plate with negative control (sample buffer) and ½ of the plate with positive control (unlabeled GTP). Briefly, the assay was performed by dispensing 2 μL of GST-Rac1 coated beads to each well of a 1536 well plate, followed by either 2 μL of sample buffer (negative control) or 2 μL of 500 μM unlabeled GTP (positive control; final concentration 166.7 μM). Finally, 2 μL FL-GTP was added to each well, then the plate was heat sealed with a pierceable foil seal and incubated at RT for 30 min. Each plate’s Z′ factor was calculated as greater than 0.5 with an average of 0.68 across the three plates (Figure 6).
We optimized the coating of Rac1 on the beads by testing the signal strength and assay window achieved over a 15 fold range of initial protein concentration from saturation down to zero (Table 1).
|Rac1 concentration (μM)||Max signal||Min signal||Z′||S/B|
The aim was to identify the optimum concentration to use while maintaining best signal to background ratio. Following optimization i.e. check that the assay was suitable for running at large scale, the assay was validated by running a set of 7000 core compounds and a set of 3000 low molecular weight compounds (LMW) (mol.wt. below 325) (see Section 3) on 2 separate occasions to assess variability. These compounds encompass the diversity of the collections that will be screened. Running an HTS campaign is a costly and fairly demanding process. For this reason we need to ensure an assay is robust (Z′ factor greater than 0.5, signal to background greater than 3, low coefficient of variation across whole plate) and reproducible i.e. active compounds will be found repeatedly if the assay was run multiple times. We therefore defined a set of criteria we need to satisfy prior to embarking on a screen . Core compounds were run at 12.5 μM and LMW at 100 μM. We use an in-house designed Tibco Spotfire® tool to analyze the data and visualize the repeatability of the assay. Validation showed the assay was performing well resulting in good agreement between the repeat runs as depicted in Figure 7 which shows a Bland-Altman plot comparing data from the 2 runs; the average difference is 0.3 and the standard deviation of the difference around 7%. We were confident that this assay was now amenable to full scale screening.
The iQue® Screener HD increases the capabilities of flow cytometry with rapid sampling and assay miniaturization with a final assay volume of 6 μL per well, using as little as 1 μL per sample with no dead volume. The iQue® Screener HD has an autosampler that delivers samples in an air gap delimited stream to the cytometer engine. The plate loading area is accessible to robotic integration and an easy to use interface allows integration of laboratory automation. The entire plate of data is processed at one time. ForeCyt® software that controls the iQue® Screener HD allows plate level annotation, analysis, and visualization of the acquired data, enabling rapid, high content, multiplexed analysis of cells and beads in suspension. To enable the throughput required, we have linked two iQue® Screener HD to an ACell benchtop automation system (HighRes Biosolutions), as shown in Figure 8, comprising a Nanoserve plate carousel and an ambient nest integrated by the Cellario® scheduling software. This simple small footprint automation system allows unattended operation as well as automatically clean the cytometers at the end of each run and has a capacity of up to 28 plates per working day. We also used a third iQue® Screener HD as a standalone instrument for backup and additional throughput.
Prior to first use, a daily clean was run on the iQue® consisting of 5 min in decontamination solution (Intellicyt), a mildly basic solution, followed by 5 min in cleaning solution (Intellicyt), a mildly acidic and surfactant solution that neutralizes the decontamination solution and a final 10 min in water. This ensures cleaning of the entire fluidics path from probe to detector. Following this procedure a QC test was run to check the performance of the iQue instruments consisting of a 2 min water test to check cleanliness of the system followed by an 8 peak (Intellicyt) and 6 peak (Intellicyt) beads test to check laser alignment and performance of the 4 fluorescence channels. The 8 peak product contains a mixture of several similar size particles with 8 different fluorescence intensities. Every particle contains a mixture of fluorophores that enables their excitation with the blue laser (488 nm) to validate the FL1, FL2 and FL3 channels of the iQue. Similarly, the 6 peak product contains a mixture of particles with 6 different fluorescence intensities excitable by the red laser to validate the FL4 channel.
All compounds for HTS in AstraZeneca are delivered in what are known as assay ready plates. Assay ready plates have the correct volume of compound in them such that on addition of the assay reagents the correct final compound concentration is achieved. Compound volumes are in the nL range and are added by a Labcyte Echo® acoustic dispenser. Using assay ready plates removes the need for intermediate dilution steps to get compounds and vehicle to the correct concentration making plate processing much simpler and faster in HTS screens.
Within the AstraZeneca HTS Centre we have 2 main collections of compounds that we screen. We have what we call the core collection that is screened at a single final concentration of 10 μM or a concentration close to this balancing solubility of the compounds with detecting weaker activity. We also have a low molecular weight collection  where we have separated out compounds with molecular weights below 325 Da that pass solubility filters. These compounds are screened at higher concentrations (typically 100 μM) to ensure we detect the activity of these compounds that potentially have better ligand efficiencies than hits that may be found in the core collection.
Rac1-coated beads were prepared by vigorously vortexing the glutathione beads, then transferring 7 mL into a 50 mL centrifuge tube. The beads were centrifuged (1000 ×
The primary screen was performed at compound concentration of 12.5 μM (100 μM for LMW) against a diversity collection of 500,000 compounds. All assay ready plates of compounds were prepared by our compound management team. The plate layout included on-board controls in the four central columns (64 wells of either 12.5 μM unlabeled GTP or 1% (v/v) DMSO as inhibitor and neutral controls, respectively). Each remaining well contained a single compound from the library, resulting in single shot screening of 1408 compounds per plate.
To assemble the assay, the Rac1-coated beads were vigorously vortexed to mix and dispensed 3 μL/well to each well of the 1536 well assay ready plate (polypropylene deep well V-bottom microplates, Greiner Bio-One) using a Multidrop™ dispenser and a small tube cassette. Assay ready plates for this assay had 7.5 nL (60 nL for low molecular weight compounds) of a 10 mM stock of compound dispensed to each well. 3 μL/well of 200 nM Bodipy-FL GTP in sample buffer was added and plates were centrifuged (250–500 ×
In the Intellicyt ForeCyt® software, we acquired flow cytometric light scatter as well as fluorescence emission in the FL1 channel (Ex 488 nm, Em 530 ± 30 nm). We gated on forward scatter and side scatter to identify the bead populations followed by forward scatter area vs. height to identify the singlet bead subpopulation. The median fluorescence of the singlet bead population was then extracted. Data files were exported from the ForeCyt® software as multiple plates in 1536 grid format as a comma-delimited text file. The files were manually imported into Genedata Screener® for analysis.
Data were normalized on a plate by plate basis using the on-board controls to calculate a % effect value and by robust Z Score. Robust Z Score is a derivation of the original Z Score calculation  substituting median for average and robust standard deviation for standard deviation and is used routinely for normalization and hit calling in the AstraZeneca HTS Centre alongside the more common 2-point normalizations using positive (inhibitor) and negative (neutral) control wells. By using robust statistical measures the calculation is resistant to outliers which are, of course, the hits in an HTS which can be missed if using the non-robust version of the equation. Robust Z Score is calculated according to the equation below (Eq. (1)) and normalizes individual wells by calculating the number of robust standard deviations the well value is away for the median of the plate central reference. In most HTS screens this central reference is the median of all the compound wells on a plate as >99% of the wells will be inactive and will define the central reference.
Hits were identified using a cut-off of −10 in robust Z score; this corresponded to an approximate change of fluorescence greater than 30% (50% for LMW) from controls.
The primary screen of 500,000 compounds took 4 weeks to complete and some summaries of the data are presented in Figure 10.
The screen ran at a throughput of 20 plates per day equivalent to 31,000 compounds per day. The overall distribution in Figure 10 shows a narrow central peak centered on zero with the left tail containing potential hits. This is a typical distribution shape seen in HTS screens and clearly shows that the assay was capable of identifying hits. The box plots shows the stability and consistency of the assay and tightness of the data across multiple plates and also allows visualization of the hits represented as the outliers on the plot. A typical plate analysis is shown depicting the controls in the central columns and a few hits scattered across the plate as dark blue wells with the histogram showing the heat map scale of the robust Z score. The assay overview (Figure 11) shows the whole set of plates (with the low molecular weight collection highlighted) run on one iQue® Screener HD highlighting the hit rate variation with the collection subset. It can be clearly seen that the hit rate in the low molecular weight set, found in the first 32 plates, is elevated above that of the core collections. This can occur due to the higher screening concentration leading to more non-specific inhibition due to common contaminants such as metals which are then ruled out by further downstream assays and SAR analysis Although not shown, the assay signal to background as well as Z′ factor  are monitored throughout the screen as markers of data quality and again indicated that this assay was of high quality.
5870 hits were identified after the primary screen representing a 1.2% overall hit rate. All hits were then tested as 10-point concentration responses (100–0.003 μM) against Rac1 as well as RhoA and CDC42 so we could assess selectivity of the compounds for Rac1. The assay is performed as described for the primary screen. All hits identified in the primary screen were serially diluted 1:3 to construct a 10-point concentration response curve. Compound concentration curves are dispensed using acoustic dispensing into assay ready plates at 150 compound curves per plate. Wells are backfilled with DMSO to keep the DMSO concentration constant in all wells. The plates were sealed and stored in the controlled atmosphere and temperature working plate store before use as for primary screen plates. 1 mM MgCl2 was added to the buffer for the RhoA assay. 82% of the tested compounds were confirmed as active with 44 identified as Rac1 selective using a ≥10 fold ratio of Rac1 IC50 vs. RhoA and Cdc42 as a cutoff. These compounds encompass a variety of chemical structures. Figure 12 shows representative curves of selective and non-selective compounds. Selected hits are being further characterized through a panel of cellular assays by the team at INSERM.
Until recently flow cytometry was considered a powerful technology dedicated to bespoke assays where just a few samples were to be measured. No medium throughput let alone high throughput screen could be run on this technology due to lack of plate handling features, time needed per sample and therefore cellular imaging was the preferred method for any high content screen. Increases of interest in phenotypic screening combined with a desire to access relevant cell models, often suspension cells, and development of plate-based sampling flow cytometers have led to the opportunity to use flow cytometry as a drug screening technology platform. The ability to perform multiplexing where different cells or particles labeled with distinct fluorophores are analyzed in parallel and multiple endpoints are measured leads to in-depth analysis of subpopulations within a sample. Such an approach results in increased productivity by decreasing timelines and cell requirements, two critical parameters for high throughput screening.
We chose to run a screen for Rac1 inhibitors on our iQue® Screener HD as it enabled us to miniaturize and run a simple and robust assay on one of our automation platforms.
We have run a successful 500,000 compound screen using the iQue® HD screener as summarized in Figure 13. By optimizing the protocol, we were able to retain high-quality data while decreasing read time per 1536 well plate to under 50 min. This allowed us to run the primary screen within 4 weeks. Although time is not the most critical criteria we consider it remains an important factor as we need to maintain the overall flow of projects through our portfolio and therefore we must decide on a suitable time frame for completion of each screen.
High throughput screening is a key method for the identification of hit and lead compounds and remains at the start of most of our drug discovery programs. As we pursue a wide range of targets we also use a wide range of assays and technologies. We have invested into several iQue® Screener systems as we updated and replaced previous detection systems and to fill a capability gap for screening suspension cells or primary cells in small sample volumes. We have successfully used the iQue® Screener systems in a variety of applications from phenotypic screening to more complex multiplex profiling. The technology has enabled several projects due to the ability to reduce cell requirement, cost and timelines.
The screen we have described here would have not been possible a few years ago but, thanks to the development of high throughput capable instruments, flow cytometry has found its place within the drug discovery process and high throughput screening in AstraZeneca. Although we decided not to multiplex our concentration response assays, it should be noted that the use of flow cytometry technology does allow for such multiplexing and indeed has been described in the literature .
The authors would like to thank Matthew Collier for his assistance during the high throughput screen and Kim Luu for her technical support with the iQue®.
Busse WW, Lemanske RF Jr. Asthma. The New England Journal of Medicine. 2001; 344(5):350-362
To T et al. Global asthma prevalence in adults: Findings from the cross-sectional world health survey. BMC Public Health. 2012; 12:204
Cockcroft DW, Davis BE. Mechanisms of airway hyperresponsiveness. The Journal of Allergy and Clinical Immunology. 2006; 118(3):551-559. quiz 560-551
Prakash YS. Airway smooth muscle in airway reactivity and remodeling: What have we learned? American Journal of Physiology. Lung Cellular and Molecular Physiology. 2013; 305(12):L912-L933
Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nature Reviews. Immunology. 2008; 8(3):183-192
Loirand G et al. Small G proteins in the cardiovascular system: Physiological and pathological aspects. Physiological Reviews. 2013; 93(4):1659-1720
Bustelo XR et al. GTP-binding proteins of the Rho/Rac family: Regulation, effectors and functions in vivo. BioEssays. 2007; 29(4):356-370
Andre G et al. Smooth muscle specific Rac1 deficiency induces hypertension by preventing p116RIP3-dependent RhoA inhibition. Journal of the American Heart Association. 2014; 3(3):e000852
Carrizzo A et al. Rac-1 as a new therapeutic target in cerebro- and cardio-vascular diseases. Current Drug Targets. 2014; 15(13):1231-1246
Halaban R. RAC1 and melanoma. Clinical Therapeutics. 2015; 37(3):682-685
Hong L et al. A Pan-GTPase inhibitor as a molecular probe. PLoS One. 2015; 10(8):e0134317
Surviladze Z et al. Identification of a small GTPase inhibitor using a high-throughput flow cytometry bead-based multiplex assay. Journal of Biomolecular Screening. 2010; 15(1):10-20
Surviladze Z et al. High throughput flow cytometry bead-based multiplex assay for identification of Rho GTPase inhibitors. Methods in Molecular Biology. 2012; 827:253-270
Murray D, Wigglesworth M. Chapter 1 HTS methods: Assay design and optimisation. In: High Throughput Screening Methods: Evolution and Refinement. London: The Royal Society of Chemistry; 2017. p. 1-15
Wigglesworth MJ et al. Increasing the delivery of next generation therapeutics from high throughput screening libraries. Current Opinion in Chemical Biology. 2015; 26:104-110
Malo N et al. Statistical practice in high-throughput screening data analysis. Nature Biotechnology. 2006; 24(2):167-175
Zhang JH et al. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. Journal of Biomolecular Screening. 1999; 4(2):67-73